FDA clears integration of OneTouch meter with WellDoc's diabetes management platform

CHESTERBROOK, Pa. — LifeScan, part of the Johnson & Johnson Diabetes Care Companies, earlier this week announced the U.S. Food and Drug Administration has cleared the wireless integration of the OneTouch Verio Flex blood glucose monitoring system with WellDoc's clinically validated diabetes management platform, BlueStar, creating a unique digital health solution for people living with Type 2 diabetes.



"Our partnership with WellDoc highlights our sustained commitment in helping to drive better health outcomes by building a more connected patient experience," stated Valerie Asbury, world wide president LifeScan. "Integrating digital solutions such as OneTouch Reveal mobile app and BlueStar will help patients self-manage their diabetes and create value for health care providers."



Using blood glucose data wirelessly and automatically transmitted from the OneTouch Verio Flex blood glucose monitoring system with built-in Bluetooth Smart Technology, WellDoc's patented clinical and behavioral engine will provide patients with individualized real-time feedback and virtual coaching based on the patient's specific treatment plan, and also help health care teams make timely diabetes management decisions.



Along with the OneTouch Reveal web and mobile app, the offering seeks to create a comprehensive, data-driven and payer-reimbursed program for the management of Type 2 diabetes.



LifeScan and WellDoc are currently working with health plans to help provide patient access for this integrated system. People with diabetes and their caregivers who are interested can ask their health plans and healthcare providers for information on integrating their OneTouch Verio Flex blood glucose monitoring system with BlueStar.